# A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency

> **NCT03075644** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 62 (actual)

## Conditions studied

- Growth Hormone Disorder
- Adult Growth Hormone Deficiency

## Interventions

- **DRUG:** somapacitan
- **DRUG:** Norditropin

## Key facts

- **NCT ID:** NCT03075644
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-03
- **Primary completion:** 2018-10-04
- **Final completion:** 2018-10-04
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2020-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03075644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03075644, "A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03075644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*